80 related articles for article (PubMed ID: 37137997)
1. Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Vega DM; Nishimura KK; Zariffa N; Thompson JC; Hoering A; Cilento V; Rosenthal A; Anagnostou V; Baden J; Beaver JA; Chaudhuri AA; Chudova D; Fine AD; Fiore J; Hodge R; Hodgson D; Hunkapiller N; Klass DM; Kobie J; Peña C; Pennello G; Peterman N; Philip R; Quinn KJ; Raben D; Rosner GL; Sausen M; Tezcan A; Xia Q; Yi J; Young AG; Stewart MD; Carpenter EL; Aggarwal C; Allen J
JCO Precis Oncol; 2022 Aug; 6():e2100372. PubMed ID: 35952319
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 as a predictive factor for non-small-cell lung cancer prognosis.
Chen L; Zhu XZ; Zhao SJ; Yang QW
Lancet Oncol; 2024 Jun; 25(6):e233. PubMed ID: 38821094
[No Abstract] [Full Text] [Related]
3. Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.
Nabet BY; Esfahani MS; Moding EJ; Hamilton EG; Chabon JJ; Rizvi H; Steen CB; Chaudhuri AA; Liu CL; Hui AB; Almanza D; Stehr H; Gojenola L; Bonilla RF; Jin MC; Jeon YJ; Tseng D; Liu C; Merghoub T; Neal JW; Wakelee HA; Padda SK; Ramchandran KJ; Das M; Plodkowski AJ; Yoo C; Chen EL; Ko RB; Newman AM; Hellmann MD; Alizadeh AA; Diehn M
Cell; 2020 Oct; 183(2):363-376.e13. PubMed ID: 33007267
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors.
Pedersen JG; Madsen AT; Gammelgaard KR; Aggerholm-Pedersen N; Sørensen BS; Øllegaard TH; Jakobsen MR
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32486146
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Mutated KRAS and Methylated HOXA9 Tumor-Specific DNA in Advanced Lung Adenocarcinoma.
Wen SWC; Andersen RF; Petersen LMS; Hager H; Hilberg O; Jakobsen A; Hansen TF
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33322500
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial assessment of ctDNA release and mutational burden predicts anti-PD(L)1 therapy outcome in nonsmall-cell lung cancer.
Fang W; Ma Y; Yin JC; Zhou H; Wang F; Bao H; Wang A; Wu X; Hong S; Yang Y; Huang Y; Zhao H; Shao YW; Zhang L
Clin Transl Med; 2020 Jan; 10(1):331-336. PubMed ID: 32508057
[No Abstract] [Full Text] [Related]
7. Practical recommendations for using ctDNA in clinical decision making.
Cohen SA; Liu MC; Aleshin A
Nature; 2023 Jul; 619(7969):259-268. PubMed ID: 37438589
[TBL] [Abstract][Full Text] [Related]
8. Blood tumor mutational burden and dynamic changes in circulating tumor DNA predict response to pembrolizumab treatment in advanced non-small cell lung cancer.
Stensgaard S; Thomsen A; Helstrup S; Meldgaard P; Sorensen BS
Transl Lung Cancer Res; 2023 May; 12(5):971-984. PubMed ID: 37323168
[TBL] [Abstract][Full Text] [Related]
9. SERS-Based Optical Nanobiosensors for the Detection of Alzheimer's Disease.
Gao F; Li F; Wang J; Yu H; Li X; Chen H; Wang J; Qin D; Li Y; Liu S; Zhang X; Wang ZH
Biosensors (Basel); 2023 Sep; 13(9):. PubMed ID: 37754114
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.
Yoshida H; Nomizo T; Ozasa H; Tsuji T; Funazo T; Yasuda Y; Ajimizu H; Yamazoe M; Kuninaga K; Ogimoto T; Hosoya K; Itotani R; Sakamori Y; Kim YH; Hirai T
Eur J Cancer; 2021 Feb; 144():317-325. PubMed ID: 33385948
[TBL] [Abstract][Full Text] [Related]
11. Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.
Uruga H; Mino-Kenudson M
Virchows Arch; 2021 Jan; 478(1):31-44. PubMed ID: 33486574
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
[TBL] [Abstract][Full Text] [Related]
13. NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
Wen SWC; Nederby L; Andersen RF; Hansen TS; Nyhus CH; Hilberg O; Jakobsen A; Hansen TF
Br J Cancer; 2023 Jul; 129(1):135-142. PubMed ID: 37137997
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors.
van der Leest P; Hiddinga B; Miedema A; Aguirre Azpurua ML; Rifaela N; Ter Elst A; Timens W; Groen HJM; van Kempen LC; Hiltermann TJN; Schuuring E
Mol Oncol; 2021 Nov; 15(11):2910-2922. PubMed ID: 34449963
[TBL] [Abstract][Full Text] [Related]
15. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
